Home Supplements That Start With E Esketamine: Comprehensive Guide to Benefits, Dosage, Effects, and Mental Health Applications

Esketamine: Comprehensive Guide to Benefits, Dosage, Effects, and Mental Health Applications

8

Esketamine is a prescription nasal spray used for adults with treatment-resistant depression and for depressive symptoms in major depressive disorder with acute suicidal ideation or behavior. It works differently from traditional antidepressants, acting on glutamate pathways to produce rapid relief for some people—often within hours to days. In 2025, its U.S. labeling expanded to allow monotherapy for treatment-resistant depression in adults, in addition to use alongside an oral antidepressant. Because it can cause sedation, dissociation, and blood-pressure rises, esketamine must be administered in a certified clinical setting with observation afterward. This guide clarifies how it works, who benefits, how it’s given, dosing schedules, and the most important safety considerations so you can discuss informed options with your clinician and set realistic expectations about outcomes and follow-up.

Key Insights on Esketamine

  • Rapid reduction in depressive symptoms for some adults with treatment-resistant depression, sometimes within 24 hours.
  • May help during psychiatric emergencies by improving depressive symptoms fast; it is not proven to reduce suicidal ideation or behavior.
  • Typical dosing is 56–84 mg per session intranasally; schedules vary by indication.
  • Important safety caveats: monitored administration, at least 2 hours of post-dose observation, and no driving until the next day after restful sleep.
  • Avoid if you have aneurysmal vascular disease, arteriovenous malformation, or intracerebral hemorrhage; discuss pregnancy and breastfeeding risks.

Table of Contents

What is esketamine and how does it work?

Esketamine is the S-enantiomer of ketamine formulated as a nasal spray for supervised use in adults with serious depressive conditions. Unlike selective serotonin reuptake inhibitors (SSRIs) and other conventional antidepressants, esketamine’s primary action is N-methyl-D-aspartate (NMDA) receptor antagonism, which indirectly boosts glutamate signaling through AMPA receptors. The downstream effect is thought to enhance synaptic plasticity and connectivity in brain regions involved in mood regulation. Patients and clinicians often describe this as “lifting the floor” of severe depression quickly, creating a window for psychotherapy, coping skills, and the slower-acting benefits of oral antidepressants to take hold.

Indications now include two distinct clinical scenarios in adults:

  • Treatment-resistant depression (TRD): depression that persists despite adequate trials of at least two oral antidepressants. As of early 2025 in the U.S., esketamine may be used as monotherapy or with an oral antidepressant for TRD.
  • Depressive symptoms in major depressive disorder with acute suicidal ideation or behavior: here esketamine is given with an oral antidepressant as part of comprehensive emergency care. Importantly, it is not approved for preventing suicide or reducing suicidal ideation or behavior; its role is to rapidly reduce depressive symptoms while broader care continues.

Esketamine is delivered intranasally in a clinic or hospital certified under a Risk Evaluation and Mitigation Strategy (REMS). Each device contains 28 mg. Doses are constructed by using two devices (56 mg) or three devices (84 mg), with short rests between sprays. Because esketamine can cause transient dissociation, sedation, and blood-pressure increases, you remain on-site for monitoring and cannot drive until the day after treatment and a restful sleep.

Mechanistically, people often ask whether esketamine “works like ketamine.” They share pharmacology and some clinical effects, but are not interchangeable. Intravenous racemic ketamine is not FDA-approved for depression; esketamine nasal spray is a specific, on-label product with standardized dosing, mandatory monitoring, and a defined evidence base. That structure is part of why programs can deliver it consistently and safely.

What to expect in a session: a pre-dose check (vitals, symptoms, medication review), dosing under staff supervision, a two-hour observation period, and a discharge readiness assessment. Some people describe altered perceptions or a “detached” feeling during the hour after dosing; staff provide a calm, low-stimulation environment and frequent reassurance. Most acute effects resolve within two hours, but you should plan the rest of the day for rest and recovery.

Finally, esketamine is one part of care—not a standalone cure. Treatment plans that combine medication management, psychotherapy, sleep and activity scheduling, and practical supports tend to produce more durable gains than medication alone.

Back to top ↑

Proven benefits: who actually improves?

Across randomized trials and modern reviews, esketamine demonstrates rapid reductions in depressive symptoms for a subset of adults with treatment-resistant depression. Improvements may be measurable within 4–24 hours after the first dose and often accumulate across the four-week induction phase. In the pivotal programs for TRD, adding intranasal esketamine to a newly initiated oral antidepressant improved depression scores and increased the proportion of responders compared with placebo nasal spray plus the same oral antidepressant. Subsequent analyses suggest meaningful functional gains (for example, on measures of role impairment), not merely score changes.

Who tends to benefit?

  • Treatment-resistant depression (TRD): Adults who have tried and not responded to at least two adequate antidepressant trials. In meta-analyses focused on randomized controlled studies, esketamine improved standardized depression ratings and response rates versus control. Some people respond quickly and robustly; others see modest changes; a minority does not respond.
  • Acute psychiatric emergencies with MDD: In patients with MDD and acute suicidal ideation or behavior, pooled phase 3 data show faster improvement in depressive symptoms (often detectable at 4–24 hours) when esketamine is added to comprehensive standard of care (hospitalization, safety planning, and a newly started or optimized antidepressant). However, regulators emphasize that esketamine is not proven to reduce suicidal ideation or behavior; hospitalization and intensive follow-up remain essential.

Clinical patterns worth noting:

  • Time course: People who respond often notice a qualitative “shift” within the first two to three treatments. Early non-response does not always predict failure—clinicians typically complete the four-week induction before judging benefit.
  • Maintenance: For TRD responders, continuing treatment at the lowest frequency that maintains stability (weekly or every two weeks) can help sustain remission or response. If symptoms return, frequency can be adjusted.
  • Function and distress: Beyond depression scores, many report reduced psychic pain, improved capacity to engage in therapy, and lower hopelessness—changes that can be particularly meaningful in severe, chronic depression.

What about older adults? Trials include people aged 65 and over, but data are more limited than in younger adults. Some older patients benefit; others experience more pronounced blood-pressure changes or dizziness. Careful monitoring is key.

Who is less likely to benefit? Predictors are still being clarified. Non-response is more likely with prominent comorbidities that complicate care (e.g., untreated substance use disorders), poor adherence to the treatment plan, or when psychosocial stressors overwhelm clinical gains. Because the mechanism targets glutamate signaling rather than serotonin or norepinephrine alone, esketamine sometimes helps people who have not responded to classic antidepressants—but it is not universal.

Finally, be cautious about over-promising. Esketamine can be life-changing for some, but it is not magic. The best outcomes come from combining it with a thoughtful, measurement-based plan that includes psychotherapy, sleep and activity routines, and practical supports.

Back to top ↑

How to use it safely in practice

Esketamine is administered only in certified clinics or hospitals that meet REMS requirements. A typical visit follows a structured protocol designed to maximize benefit and minimize risk.

Before the first dose

  1. Eligibility review: Confirm the indication (TRD or MDD with acute suicidal ideation or behavior), past antidepressant trials, and medical history.
  2. Contraindications check: Aneurysmal vascular disease or arteriovenous malformation, intracerebral hemorrhage, or known hypersensitivity to esketamine/ketamine exclude use.
  3. Risk discussion and consent: Review potential adverse effects (dissociation, sedation, blood-pressure rises, nausea, urinary symptoms, abuse/misuse potential), driving restrictions, and pregnancy/breastfeeding considerations.
  4. Medication review: Identify CNS depressants (e.g., benzodiazepines, opioids), stimulants, or MAOIs that may increase risks; plan timing and dose adjustments where appropriate.
  5. Baseline measurements: Blood pressure, heart rate, symptom scales, and (if relevant) urine pregnancy test.

At each session

  • Preparation: Avoid food for two hours and liquids for 30 minutes prior (to reduce nausea risk).
  • Dosing: The clinician gives 56 mg or 84 mg intranasally using 2 or 3 single-use devices, with a brief rest between devices.
  • Setting: Quiet room, low stimulation, eyeshades or calming music if allowed by clinic policy.
  • Monitoring: Continuous observation of consciousness, dissociation, anxiety, respiration, and vitals.
  • Observation period: Remain on site for at least two hours post-dose; discharge only after clinical stability is documented.

After the session

  • No driving or operating machinery until the next day after a restful sleep. Arrange transportation in advance.
  • Hydration and rest: Light meals and fluids may help once nausea subsides.
  • Follow-up: Use measurement-based care (e.g., MADRS or PHQ-9) to track response and guide frequency in maintenance.

Program features that improve safety and outcomes

  • A calm, predictable protocol lowers anxiety and helps patients tolerate transient dissociation.
  • Measurement-based adjustments (dose, frequency) reduce overtreatment and under-treatment.
  • Integrated psychotherapy: Schedule therapy to capitalize on periods of improved cognitive flexibility and motivation.
  • Relapse planning: Teach early-warning signs and steps to take if symptoms resurface between sessions.

Practical tips

  • Bring comfortable clothing and, if allowed, calming audio.
  • Expect altered perceptions (time distortion, floating sensations). These are time-limited and monitored; grounding strategies help.
  • Report urinary urgency, pelvic discomfort, or persistent cognitive fog—early evaluation prevents complications.
  • Keep a medication and session log; share updates at each visit.

Back to top ↑

Esketamine dosing: how much and how often?

Esketamine dosing is indication-specific and individualized for efficacy and tolerability. All doses are expressed in milligrams (mg) of intranasal esketamine.

Devices and administration

  • Each single-use device = 28 mg (two sprays).
  • 56 mg dose = 2 devices; 84 mg dose = 3 devices.
  • Use a brief rest (about five minutes) between devices to minimize drip-through and improve absorption.

Treatment-resistant depression (adults)

  • Induction (Weeks 1–4): 56 mg or 84 mg, twice weekly.
  • Maintenance (Week 5–8): 56 mg or 84 mg, once weekly.
  • Long-term (Week 9 and beyond): 56 mg or 84 mg every 2 weeks or once weekly, individualized to the least frequent schedule that maintains remission or response.
  • Assess benefit at the end of the 4-week induction; continue only if there’s clear improvement.

MDD with acute suicidal ideation or behavior (adults)

  • Dose: 84 mg, twice weekly for 4 weeks, with the option to reduce to 56 mg based on tolerability.
  • Co-treatment: Always given with an oral antidepressant and comprehensive standard of care.
  • Duration note: Treatment with esketamine beyond 4 weeks for this indication has not been systematically evaluated; reassess the plan after the fourth week.

Missed sessions and adjustments

  • If a session is missed and symptoms are stable, resume the current schedule.
  • If symptoms worsen, clinicians may temporarily increase frequency (e.g., from every two weeks back to weekly) until stability returns.
  • Dose selection (56 vs 84 mg) balances benefits and side effects; some people tolerate 84 mg well and benefit from it, while others do best at 56 mg.

Pre- and post-dose precautions

  • Check blood pressure before and after dosing; manage elevations per clinic protocol.
  • Avoid driving until the following day after restful sleep.
  • Allow at least two hours of on-site observation after each dose.

When to stop

  • Lack of meaningful symptom improvement by the end of the induction phase, persistent intolerable side effects, emergence of contraindications, or patient preference are common reasons to discontinue.
  • If stopped after good response, relapse prevention planning (psychotherapy, optimized oral meds, sleep/activity routines) reduces the risk of symptom return.

Back to top ↑

Risks and side effects to watch for

Esketamine’s safety profile is well characterized, and clinics follow standardized protocols to manage predictable effects. Even so, planning and awareness are essential.

Common, usually transient effects (often within the first 1–2 hours)

  • Dissociation and perceptual changes: depersonalization, altered time sense; typically self-limited under supervision.
  • Sedation and dizziness: plan quiet rest; stand slowly to prevent falls.
  • Nausea or vomiting: fasting guidelines and antiemetics (if needed) help.
  • Blood-pressure increases: usually brief; more pronounced in people with cardiovascular risk.
  • “Feeling drunk,” vertigo, paresthesia, anxiety, or headache: typically resolve during observation.

Serious risks (uncommon but important)

  • Excessive sedation or respiratory depression: rare with intranasal doses but monitored closely; medical support is available on site.
  • Significant hypertension: risk is higher in those with cardiovascular or cerebrovascular disease; treat per protocol before discharge.
  • Cognitive effects: short-term impairment of attention and reaction time; hence the no-driving rule until the next day after restful sleep.
  • Urinary symptoms: long-term/high-frequency exposure to ketamine-like compounds has been linked to cystitis; report urgency, frequency, or pelvic pain.
  • Abuse and misuse potential: esketamine is a controlled substance. Supervised dosing under REMS reduces diversion risk; disclose any personal or family history of substance use disorders.
  • Reproductive risk: may cause fetal harm; discuss contraception and pregnancy planning before starting. Breastfeeding is not recommended during treatment.

Drug interactions and special populations

  • CNS depressants (e.g., benzodiazepines, opioids): may increase sedation and respiratory risk; coordinated dosing and timing reduce hazards.
  • Psychostimulants: can amplify blood-pressure responses; monitor closely.
  • MAOIs: theoretical hypertensive risk; coordinate with your prescriber.
  • Older adults: similar antidepressant benefits for some, but monitor more closely for blood-pressure changes and balance issues.
  • Hepatic impairment: exposure may increase; dosing and monitoring may need adjustments.
  • History of psychosis or mania: not an absolute contraindication, but careful screening and monitoring for symptom activation are critical.

Monitoring that matters

  • Blood pressure and heart rate before and after dosing.
  • Standardized symptom scales to separate true benefit from placebo effects.
  • Side-effect logs to tailor dose and frequency intelligently.
  • Periodic reassessment of the ongoing need for treatment and the lowest effective frequency.

Bottom line: Most side effects are short-lived and manageable in a supervised setting. Honest communication about prior substance use, cardiovascular history, and current medications keeps treatment safer.

Back to top ↑

Who should avoid esketamine or use caution?

Esketamine is not right for everyone. Clinicians screen out high-risk situations and adapt plans to individual health profiles. Discuss your full medical history to weigh risks and benefits carefully.

Do not use (contraindications)

  • Aneurysmal vascular disease (e.g., thoracic or abdominal aorta, intracranial or peripheral arteries) or arteriovenous malformation.
  • Intracerebral hemorrhage.
  • Known hypersensitivity to esketamine, ketamine, or formulation components.

Strong caution or additional planning

  • Pregnancy: Potential for fetal harm; avoid unless potential benefit clearly outweighs risks. Discuss effective contraception before starting; inform your clinician immediately if pregnancy occurs.
  • Breastfeeding: Not recommended while receiving esketamine; consider pumping and discarding during treatment, with a plan to resume later if appropriate.
  • Uncontrolled hypertension, significant cardiovascular or cerebrovascular disease: optimize control before treatment; monitor vitals closely at each session.
  • Active substance use disorder or high diversion risk: the REMS framework lowers risk, but candid discussion and, when needed, linkage to addiction services are essential.
  • Severe sleep apnea, respiratory compromise, or high fall risk: plan additional monitoring and supports.
  • Older age with balance issues or polypharmacy: start cautiously, reassess frequently.
  • Co-occurring psychiatric conditions:
  • Bipolar disorder: treat mood stabilization first; monitor for mania/hypomania.
  • Psychotic disorders: proceed only with careful monitoring and a clear plan to address potential symptom activation.
  • Severe anxiety disorders: dissociative experiences can be distressing; pre-session coaching and a calm environment help.

Situations requiring structured planning

  • Limited social support or transportation: clinics can help arrange safe rides; do not drive until the next day after a restful sleep.
  • Work with safety-sensitive duties (e.g., operating machinery): schedule sessions to protect recovery time and occupational safety.
  • Concurrent benzodiazepines or opioids: coordinate timing to limit additive sedation.

Alternatives and complements

If esketamine is unsuitable, evidence-based options remain: optimized combinations of oral antidepressants, psychotherapy (CBT, IPT, behavioral activation), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and—off-label in some settings—intravenous ketamine under expert care. Shared decision-making, using measurement-based care, helps match the right intensity and modality to your goals and constraints.

Back to top ↑

References

Medical Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Esketamine is a prescription medication that must be administered under clinical supervision. Always consult your physician or qualified mental health professional about your specific situation, including risks, benefits, alternatives, and appropriate monitoring. If you are in crisis or thinking about suicide, seek immediate help from local emergency services or a crisis hotline.

If you found this article helpful, please consider sharing it on Facebook, X (formerly Twitter), or your preferred platform, and follow us for future updates. Your support helps us continue producing careful, people-first guides.

facebookShare on Facebook
TwitterPost on X
FollowFollow us

RELATED ARTICLESMORE FROM AUTHOR